Disclosed herein are benzamide piperidine compounds of general formula I, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. The compounds are intended for use as 5-HT4 receptor agonists and as such are useful in the treatment of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer&rsquos disease, cognitive impairment, emesis, migraine, neurological disease, pain, cardiovascular disorder, cardiac failure, cardiac arrhythmia, diabetes or apnea syndrome. Examples of particularly preferred compounds include: N-((1-(3-(1,2,4-triazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide, N-((1-(3-(tetrazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide, N-((1-(3-(2-methylimidazol-l-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide, N-((1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide.
